



March 17, 2009
Announcement no. 03

Launch of APC-PCI ELISA Kit

BioPorto has launched an APC-PCI ELISA Kit for the determination of the APC-PCI complex. BioPorto's results show that the level of APC-PCI can identify the group of sepsis patients who will benefit from a treatment with activated protein C (a therapy marketed by Eli Lilly under the name "Xigris"). BioPorto's new assay for research use will enable clinical studies and validation processes which in turn will prepare the way for routine diagnostic use of the APC-PCI assay. Only BioPorto markets an APC-PCI assay.

APC-PCI stands for activated protein C-protein C inhibitor complex, which is formed in very small amounts in the blood when blood clotting is activated and the clotting-regulating protein C is also activated. Activated protein C (APC) has inhibitory actions on both blood clotting and inflammation, so that the recombinant protein (marketed by Eli Lilly under the name Xigris) can be used to treat patients with severe sepsis. BioPorto's assay can be used both for the measurement of protein C-activation in patients with severe sepsis and in patients with thrombotic conditions.

The market potential within the sepsis area comes to more than 7 million assays a year throughout the western world. Following the selection of sepsis patients who would benefit from APC treatment, the use of the test could lead to up to a 3-fold increase in the cost-effectiveness of the treatment, saving 2/3 of current costs incurred by the unnecessary treatment of unresponsive patients and at the same time avoiding serious side-effects. This reduction in costs might be able to reestablish APC treatment as a therapeutic option for patients with severe sepsis.

BioPorto has applied for a patent covering the diagnostic use of the APC-PCI marker to select patients with severe sepsis for special treatment. The company has positive indications that the patent concerning the diagnostic method can be issued. The BioPorto APC-PCI analysis comprises a monoclonal antibody that monitors the activity of the systems involving the protein C inhibitor. Within the sepsis area, BioPorto has obtained exclusive rights for the concerned antibody, as patented by Forskarpatent Syd. The rights cover all assay formats such as ELISA, point-of-care and automated systems.

The sales of the new assay are included in the budget for 2009 and the expectations for 2009 therefore remain unchanged.

Further information:

Thea Olesen, CEO
Christina Tønnesen, Investor Relations
Tel.: +45 4529 0000
E-mail: investor@bioporto.com